Last updated: 2026-09-16 11:41:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Pharvaris N.V. (PHVS) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $38.96, with a market capitalisation of $2.73B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $20.65 to $43.25. This page covers its latest market performance, valuation, price trends and company information.
$2.73B | |
$38.31 | |
$43.25 | |
$1.77 | |
$38.06 | |
67.00 | |
691.49K | |
-- | |
$43.25 | |
$20.65 | |
-- | |
-- |
Pharvaris N.V. (PHVS) is trading at $38.96 in pre-market trading as of 2026-09-16 11:36:00, up 2.35% ($0.89) from the previous close of $38.06
Pre-market trading shows how investors are pricing PHVS before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Pharvaris N.V. (PHVS) moved from $35.25 to $38.96, representing a gain of 10.51% ($3.70).
The stock traded between $35.21 and $43.25 during the period. The latest price is near the middle of the 7-day range, indicating strong upward.
The average daily volume was 1.97 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 81.0%
PHVS is currently trading at $38.96, placing it 81.0% of the way from its 52-week low of $20.65 to its 52-week high of $43.25. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.
| Employees | 129 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Pharvaris N.V. (PHVS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.